Get started
Author

Krystal Merdinger

Observed institution: Oncoceutics (United States)
OpenAlex ID: A5037362995
Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201
2019 · Andrew S. Chi, Rohinton S. Tarapore, et al. · Journal of Neuro-Oncology · 200
Biological activity of weekly ONC201 in adult recurrent glioblastoma patients
2019 · Isabel Arrillaga-Romany, Yazmin Odia, et al. · Neuro-Oncology · 94
PDF
ONC201 in previously-irradiated pediatric H3 K27M-mutant glioma.
2019 · Sharon L. Gardner, Jeffrey C. Allen, et al. · Journal of Clinical Oncology · 24
Pdct-12. Clinical Efficacy of Onc201 in Thalamic H3 K27m-mutant Glioma
2019 · Abed Rahman Kawakibi, Sharon Gardner, et al. · Neuro-Oncology · 4
Single agent ONC201 in adult recurrent H3 K27M-mutant glioma.
2019 · Isabel Arrillaga, Sylvia Kurz, et al. · Journal of Clinical Oncology · 4
Hgg-18. Clinical Efficacy of Onc201 in Thalamic H3 K27m-mutant Glioma
2020 · Abed Rahman Kawakibi, Rohinton S Tarapore, et al. · Neuro-Oncology · 3
PDF
Actr-34. Integrated Clinical Experience With Onc201 in Previously-treated H3 K27m-mutant Glioma Patients
2018 · Andrew Chi, Isabel Arrillaga-Romany, et al. · Neuro-Oncology · 3
PDF
Actr-34. Single Agent Onc201 in Previously-treated, Progressive Adult H3 K27m-mutant Glioma
2019 · Isabel Arrillaga-Romany, Sylvia Kurz, et al. · Neuro-Oncology · 1
PDF
Dipg-52. Phase I Clinical Trial of Onc201 in Pediatric H3 K27m-mutant Glioma or Newly Diagnosed Dipg
2020 · Sharon Gardner, Rohinton Tarapore, et al. · Neuro-Oncology
PDF
Pdct-06. Phase 1 Study of Onc201 in Pediatric Patients With H3 K27m-mutant High Grade Glioma or Newly Diagnosed Dipg
2018 · Sharon Gardner, Fernando Suarez, et al. · Neuro-Oncology
PDF
Works count: 10
Citation count: 333
H-index: 4
I10-index: 3
Year
Topic
Type